A prospective study on 32 patients with advanced-stage HCC confirmed an increase in the intratumoral CD8+ T cell population after RFA combined with tremelimumab, an anti-CTLA4 antibody [48]. This evidence concerns the gene CTLA4 and hepatocellular carcinoma.